Top Markets
Coin of the day
Sangamo Therapeutics, Inc. Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

GBY
Hisse Senetlerindeki Sıralama #11086
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines designed to significantly improve patients' lives. The company employs cutting-edge platform technologies, including gene therapy, cell therapy, genome editing, and genome regulation. Central to their technological approach is the zinc finger protein (ZFP) platform, which provides both ZFP nucleases for precise DNA sequence modification (allowing for gene addition or knockout) and ZFP transcription factors for upregulating or downregulating gene expression. Their development pipeline includes SB-525, currently in a Phase III AFFINE clinical trial for hemophilia A; ST-920, a gene therapy in Phase I/II STAAR trials for Fabry disease; and SAR445136, a cell therapy undergoing Phase I/II PRECIZN-1 trials for sickle cell disease. Additionally, Sangamo is advancing TX200, a chimeric antigen receptor for HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502 for synucleinopathies, which include Parkinson's disease and other neuromuscular disorders. The company maintains extensive collaborative and strategic partnerships with prominent organizations such as Biogen MA, Inc., Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Inc., and F. Hoffmann-La Roche Ltd. Originally incorporated in 1995 as Sangamo BioSciences, Inc., the company adopted its current name in January 2017 and is headquartered in Brisbane, California.
Hisse Fiyatı
$5.21
Son senkronizasyon: 2022-08-11
Piyasa Değeri
$745.49M
Değişim (1 gün)
0.15%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Sangamo Therapeutics, Inc. (GBY)

Kategori

Sangamo Therapeutics, Inc. (GBY) için P/S oranı
2026 itibarıyla P/S oranı TTM: 0
Sangamo Therapeutics, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/S oranı 0 idi.
Sangamo Therapeutics, Inc. için P/S oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/S oranı
Şirket P/S Oranı P/S Oranı Farkı Ülke
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH